Business Wire: June 9, 2016 – ARDSLEY, NY, U.S.A. – Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced pharmacokinetic (PK) data from a phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption compared to oral and nasal…
